• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估 COVID-19 四种变异株和疫苗接种覆盖率对马耳他两年内死亡率的影响:一项观察性病例研究。

Assessing the impact of the four COVID-19 variants and the vaccine coverage on mortality in Malta over 2 years: An observational case study.

机构信息

Department of Anatomy, University of Malta, Msida, Malta.

Mater Dei Hospital, Msida, Malta.

出版信息

Front Public Health. 2022 Sep 23;10:1018505. doi: 10.3389/fpubh.2022.1018505. eCollection 2022.

DOI:10.3389/fpubh.2022.1018505
PMID:36211652
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9541139/
Abstract

BACKGROUND

Mortality may quantify a population's disease burden. Malta, like other European countries, experienced COVID-19 surges in cases and mortality across the pandemic. This study assesses COVID-19's mortality impact, while exploring the effects of the four dominant COVID-19 variants and that of the vaccination coverage on the Maltese population.

METHODS

COVID-19 data (cases, mortality, positivity, and vaccination rates) was obtained from the websites of the European Center for Disease Prevention and Control and the Malta Ministry of Health. Data was categorized into the four periods according to reported dominant COVID-19 variant. Years of life lost (YLL) and Case-Fatality-Ratio (CFR) for each period were estimated. CFR was also estimated for the pre-vaccine and post-vaccine periods.

RESULTS

The original COVID-19 period (36 weeks) had the highest YLL (4,484), followed by the Omicron variant period (12 weeks; 1,398). The Alpha variant period (7 weeks) had the highest CFR (1.89%) followed by the Original COVID-19 (1.35%). The pre-vaccine (1.59%) period had higher CFR than the post-vaccine period (0.67%).

CONCLUSION

Various factors contributed to mortality, but the variant's infectivity, transmissibility, and the effectiveness of the vaccine against the variant play an important role. Reducing mortality by embracing mass vaccination that targets current variants along with other non-pharmaceutical interventions remains paramount.

摘要

背景

死亡率可以量化一个人群的疾病负担。马耳他与其他欧洲国家一样,在整个大流行期间经历了 COVID-19 病例和死亡率的激增。本研究评估了 COVID-19 的死亡率影响,同时探讨了四种主要 COVID-19 变体的影响以及疫苗接种覆盖率对马耳他人口的影响。

方法

从欧洲疾病预防控制中心和马耳他卫生部的网站获取 COVID-19 数据(病例、死亡率、阳性率和疫苗接种率)。根据报告的主要 COVID-19 变体,将数据分为四个时期。估计每个时期的生命损失年 (YLL) 和病例病死率 (CFR)。还估计了疫苗接种前和疫苗接种后的 CFR。

结果

原始 COVID-19 期(36 周)的 YLL 最高(4484),其次是奥密克戎变体期(12 周;1398)。阿尔法变体期(7 周)的 CFR 最高(1.89%),其次是原始 COVID-19 期(1.35%)。疫苗接种前(1.59%)时期的 CFR 高于疫苗接种后(0.67%)时期。

结论

各种因素导致了死亡率,但变体的传染性、传播性以及疫苗对变体的有效性起着重要作用。通过接种针对当前变体的大规模疫苗接种以及其他非药物干预措施来降低死亡率仍然至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3764/9541139/f2c57bcb1a6a/fpubh-10-1018505-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3764/9541139/d0fa946df4ed/fpubh-10-1018505-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3764/9541139/b016f37835c0/fpubh-10-1018505-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3764/9541139/f2c57bcb1a6a/fpubh-10-1018505-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3764/9541139/d0fa946df4ed/fpubh-10-1018505-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3764/9541139/b016f37835c0/fpubh-10-1018505-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3764/9541139/f2c57bcb1a6a/fpubh-10-1018505-g0003.jpg

相似文献

1
Assessing the impact of the four COVID-19 variants and the vaccine coverage on mortality in Malta over 2 years: An observational case study.评估 COVID-19 四种变异株和疫苗接种覆盖率对马耳他两年内死亡率的影响:一项观察性病例研究。
Front Public Health. 2022 Sep 23;10:1018505. doi: 10.3389/fpubh.2022.1018505. eCollection 2022.
2
Protecting our vulnerable in the midst of the COVID-19 pandemic: lessons learnt from Malta.在 COVID-19 大流行期间保护我们的弱势群体:来自马耳他的经验教训。
Public Health. 2021 Sep;198:270-272. doi: 10.1016/j.puhe.2021.07.043. Epub 2021 Aug 11.
3
Mortality comparisons of COVID-19 with all-cause and non-communicable diseases in Cyprus, Iceland and Malta: lessons learned and forward planning.塞浦路斯、冰岛和马耳他的 COVID-19 死亡率与全因死亡率和非传染性疾病死亡率的比较:经验教训和前瞻性规划。
Public Health. 2022 Jan;202:52-57. doi: 10.1016/j.puhe.2021.03.025. Epub 2021 Apr 21.
4
Same Pandemic Yet Different COVID-19 Vaccination Roll-Out Rates in Two Small European Islands: A Comparison between Cyprus and Malta.同一场疫情下,欧洲两个小岛上的新冠疫苗接种率却有所不同:塞浦路斯与马耳他的对比
Healthcare (Basel). 2022 Jan 24;10(2):222. doi: 10.3390/healthcare10020222.
5
Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.在疫苗接种前时代,按年龄、时间和地理位置划分的 COVID-19 感染病死率变化:系统分析。
Lancet. 2022 Apr 16;399(10334):1469-1488. doi: 10.1016/S0140-6736(21)02867-1. Epub 2022 Feb 24.
6
Estimating the direct Covid-19 disability-adjusted life years impact on the Malta population for the first full year.估算新冠疫情第一年对马耳他人口造成的直接伤残调整生命年影响。
BMC Public Health. 2021 Oct 9;21(1):1827. doi: 10.1186/s12889-021-11893-4.
7
A Year of COVID-19 Pandemic Roller-Coaster: The Malta Experience, Lessons Learnt, and the Future.《新冠疫情过山车:马耳他的经验、教训和未来》
Disaster Med Public Health Prep. 2022 May 2;17:e153. doi: 10.1017/dmp.2022.100.
8
COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.印度的新冠疫情动态、严重急性呼吸综合征冠状病毒2(SARS-CoV-2)德尔塔变异株及其对疫苗接种的影响
medRxiv. 2021 Nov 22:2021.06.21.21259268. doi: 10.1101/2021.06.21.21259268.
9
Differences in the case fatality risks associated with SARS-CoV-2 Delta and non-Delta variants in relation to vaccine coverage: An early ecological study in the United Kingdom.与疫苗接种覆盖率相关的 SARS-CoV-2 德尔塔变体和非德尔塔变体的病例病死率风险差异:英国的一项早期生态学研究。
Infect Genet Evol. 2022 Jan;97:105162. doi: 10.1016/j.meegid.2021.105162. Epub 2021 Nov 27.
10
A year of Covid-19: experiences and lessons learnt by small European island states-Cyprus, Iceland and Malta.《Covid-19 之年:欧洲小岛国的经验与教训——塞浦路斯、冰岛和马耳他》
Eur J Public Health. 2022 Apr 1;32(2):316-321. doi: 10.1093/eurpub/ckab217.

本文引用的文献

1
Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes.奥密克戎或德尔塔变异株感染及重症的 COVID-19 疫苗有效性评估。
JAMA Netw Open. 2022 Sep 1;5(9):e2232760. doi: 10.1001/jamanetworkopen.2022.32760.
2
Effectiveness of COVID-19 Vaccination in Preventing All-Cause Mortality among Adults during the Third Wave of the Epidemic in Hungary: Nationwide Retrospective Cohort Study.匈牙利第三波疫情期间新冠疫苗接种对预防成年人全因死亡的有效性:全国性回顾性队列研究
Vaccines (Basel). 2022 Jun 24;10(7):1009. doi: 10.3390/vaccines10071009.
3
Public health impact of covid-19 vaccines in the US: observational study.
美国新冠疫苗的公共卫生影响:观察性研究。
BMJ. 2022 Apr 27;377:e069317. doi: 10.1136/bmj-2021-069317.
4
Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21.估算2019冠状病毒病大流行造成的超额死亡率:2020 - 2021年与2019冠状病毒病相关死亡率的系统分析
Lancet. 2022 Apr 16;399(10334):1513-1536. doi: 10.1016/S0140-6736(21)02796-3. Epub 2022 Mar 10.
5
Waning of COVID-19 vaccine effectiveness: individual and public health risk.新冠病毒疫苗效力的减弱:个人与公共健康风险
Lancet. 2022 Mar 5;399(10328):887-889. doi: 10.1016/S0140-6736(22)00282-3. Epub 2022 Feb 23.
6
Comparative Analysis of Mortality From Coronavirus Disease 2019 Across the European Union Countries and the Effects of Vaccine Coverage.欧盟国家2019冠状病毒病死亡率的比较分析及疫苗接种覆盖率的影响
Open Forum Infect Dis. 2022 Feb 5;9(3):ofac006. doi: 10.1093/ofid/ofac006. eCollection 2022 Mar.
7
How well can Omicron evade immunity from COVID vaccines?奥密克戎变异株对新冠疫苗诱导的免疫的逃逸能力如何?
Nature. 2022 Feb 2. doi: 10.1038/d41586-022-00283-4.
8
Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants.新冠疫苗接种对阿尔法和德尔塔变异株传播的影响。
N Engl J Med. 2022 Feb 24;386(8):744-756. doi: 10.1056/NEJMoa2116597. Epub 2022 Jan 5.
9
The fastest national COVID vaccination in Europe - Malta's strategies.欧洲速度最快的国家新冠疫苗接种——马耳他的策略。
Health Sci Rev (Oxf). 2021;1:100001. doi: 10.1016/j.hsr.2021.100001. Epub 2021 Oct 4.
10
Covid-19: Vaccines are highly effective in preventing deaths from delta variant, study indicates.
BMJ. 2021 Oct 21;375:n2582. doi: 10.1136/bmj.n2582.